Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Lung cancer - facts and figures
- Change in lung cancer survival: 1974-2001
- Magnitude of lung cancer burden in the US: 2006
- Non-small cell lung cancer (NSCLC) - 2009
- EGFR inhibitors in lung cancer
- EGFR targeted therapeutics (1)
- Mechanisms of EGFR receptor activation
- Structures of EGFR-TK inhibitors
- Erlotinib vs. placebo
- EGFR mutations
- Somatic mutations in EGFR
- Patients with EGFR mutations treated with TKIs
- Prognostic information from mutant EGFR studies
- EGFR inhibitors effect on EGFR mutant cancers
- EGFRL858R is more sensitive to gefitinib than WT
- EGFR mutant NSCLC cell lines depend on EGFR
- Prevalence of EGFR mutations in cancer patients
- Are EGFR TKIs better than chemotherapy?
- IPASS - study design
- Progression-free survival (PFS) in ITT population
- The impact of EGFR mutation on response rate
- EGFR mutation effect on progression-free survival
- EURTAC-SLCG study design
- Questions for treatment naive EGFR mutant
- TRIBUTE trial: chemotherapy + erlotinib or placebo
- CALGB 30406 phase II study: trial design
- EGFR targeted therapeutics (2)
- Cetuximab in NSCLC
- FLEX clinical trial: chemotherapy +/- cetuximab
- FLEX overall survival
- FLEX: response rate and PFS
- Identifying predictors of cetuximab response
- Subsets of NSCLC cell lines produce amphiregulin
- Amphiregulin producing EGFR WT cell lines
- Cell cycle arrest in amphiregulin producing cells
- Emergence of resistance to EGFR TKIs
- Mechanisms of gefitinib/erlotinib resistance
- EGFR signaling in EGFR mutant NSCLC
- Development of gefitinib/erlotinib resistance
- EGFR T790M mutation
- Kinase mutations associated with drug resistance
- Irreversible EGFR inhibitors
- Irreversible EGFR TKIs affect EGFR T790M
- Irreversible EGFR inhibitors in trials
- Second generation EGFR TKIs
- MET amplification
- MET amplification and it's effect on resistance
- Efficacy of XL184 in vitro and in vivo
- MET inhibitors in trials
- Clinical resistance is heterogeneous
- Resistance mechanisms in resistant NSCLC
- Clinical strategies for gefitinib/erlotinib resistances
- Lung adenocarcinoma 2009 - genetically diverged
- Somatic mutations in NSCLC
- Targeting of other lung cancer oncogenes
- Lung cancer therapy in 2009
Topics Covered
- Lung cancer: facts and figures
- Lung cancer survival
- Lung cancer burden
- EGFR targeted therapeutics
- EGFR mutations
- Why Do EGFR inhibitors work so well in EGFR mutant cancers?
- Are EGFR TKIs better than chemotherapy?
- Emergence of resistance to EGFR TKIs
- Mechanisms of Gefitinib/Erlotinib resistance
- EGFR signaling in EGFR mutant NSCLC
- Analogous kinase mutations associated with drug resistance
- Irreversible EGFR inhibitors
- Clinical resistance is heterogeneous
- Therapeutic targeting of other oncogenes in lung cancer
- Incorporating genomics into treatment
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Janne, P. (2009, November 17). EGFR targeted therapies in lung cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 23, 2024, from https://doi.org/10.69645/IEIZ1830.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Pasi Janne has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
EGFR targeted therapies in lung cancer
A selection of talks on Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Pasi Janne from the Dana Farber Cancer Institute in Boston, Massachusetts.
I'm going to talk today on the use of
epidermal growth factor receptor targeted therapies in lung cancer.
0:13
As a background to the presentation today,
I wanted to discuss the incidence of lung cancer.
Lung cancer accounts for over 1 million cases of new cancer diagnosed
annually around the world and for about
200,000 new individuals diagnosed in the United States.
In the United States, it is the most common cause of cancer death for men and women,
and unfortunately, the cure rate remains only at 15 percent.
Approximately 85 percent of patients currently diagnosed with
lung cancer are either former or current smokers,
while a significant minority, 10 to 15 percent, are
individuals that have never smoked cigarettes and yet develop lung cancer.
Unfortunately, the median survival is also quite low,
remaining only about 8 to 10 months,
and the impact of chemotherapy has been relatively limited over the last 25 years.
0:59
This slide shows the change in
five-year survival in lung cancer over the last several decades.
As you can see in the mid 1970s, it remained about 12 percent,
and although there's been improvements,
and these are statistically significant into the 21st century,
these are only modest at best.
This slide demonstrates the number of
1:17
new cases and the number of deaths in
men and women in the United States from lung cancer.
As you can see, it's approximately 200,000 new
individuals diagnosed every year and unfortunately,
about 160,000 of these individuals will succumb to their disease annually.
1:34
We think about lung cancer and specifically non-small cell lung cancer.
It is also not one disease.
And the understanding of how this is not one disease has led
to great advances in the therapies for lung cancer.
The most common histologic subtype of lung cancer is adenocarcinoma of the lung,
accounting for approximately 65 percent of new cases.
A significant minority is made up by squamous cell carcinoma
and then with other histologic subtypes rounding up the rest.
Because therapies, specifically chemotherapy,